JIUN-KAE JACK LEE to Survival Rate
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Survival Rate.
Connection Strength
0.295
-
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93.
Score: 0.036
-
The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett. 2006 Jul 28; 239(1):136-43.
Score: 0.025
-
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
Score: 0.020
-
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 1995 Aug; 13(8):1893-903.
Score: 0.012
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.
Score: 0.012
-
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
Score: 0.011
-
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21.
Score: 0.011
-
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.
Score: 0.011
-
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
Score: 0.010
-
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
Score: 0.010
-
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
Score: 0.010
-
Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99.
Score: 0.009
-
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
Score: 0.009
-
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21.
Score: 0.009
-
Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74.
Score: 0.009
-
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.
Score: 0.009
-
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52.
Score: 0.009
-
Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep; 136(3):701-709.
Score: 0.008
-
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
Score: 0.008
-
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008 Mar 01; 112(5):1058-65.
Score: 0.007
-
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20; 25(15):1974-8.
Score: 0.007
-
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006 Jun 01; 106(11):2428-36.
Score: 0.007
-
Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7.
Score: 0.006
-
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003 Jan; 39(1):55-61.
Score: 0.005
-
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
Score: 0.004
-
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
Score: 0.004
-
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Mar-Apr; 3(2):92-9.
Score: 0.003
-
p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996 Apr 17; 88(8):519-29.
Score: 0.003
-
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13.
Score: 0.003
-
Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995 Dec; 60(6):1563-70; discussion 1570-2.
Score: 0.003
-
Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 1991 Jun 15; 67(12):3131-5.
Score: 0.002